Oral BPC 157 and administration routes

BPC 157 is administered by subcutaneous injection, intramuscular injection, intravenous infusion, oral capsules, sublingual troches, and nasal spray — each with different bioavailability, different dosing requirements, and different best-use cases. Here is the full breakdown.

The full route comparison

BPC 157 is one of the few research peptides where administration route is a genuine debate, not just a convenience question. Most peptides are delivered by injection because oral bioavailability is prohibitively low — the molecule is broken down by gastric acid and digestive enzymes before it can reach the bloodstream. BPC 157 is unusual because the parent protein (Body Protection Compound) was originally isolated from gastric juice, which means it evolved to be stable in exactly the environment that destroys most peptides. This gives oral BPC 157 a real (though still limited) rationale that does not apply to other injectable peptides.

Subcutaneous and intramuscular injection

Subcutaneous injection is the default route in the published research literature and in most peptide community protocols. The peptide is reconstituted with bacteriostatic water, drawn into a U-100 insulin syringe, and injected into subcutaneous fat — typically the abdomen, thigh, or upper arm. Intramuscular injection follows the same preparation but targets muscle tissue; some users prefer it for muscle or tendon injuries because it allows local injection near the affected tissue.

The reconstitution math is covered in detail on the dosage page. A 5 mg vial reconstituted with 2 mL of bacteriostatic water gives a concentration of 2,500 mcg/mL; a 250 mcg dose is 0.10 mL (10 units on a standard insulin syringe). BPC 157 peptide injections are what the peer-reviewed dosing protocols refer to when they cite specific microgram doses, so this is the most validated route.

Injection site reactions (mild redness, itching, occasional bruising) are the most common reported side effect of subcutaneous BPC 157. These are almost always self-limited and resolve within hours. Rotating injection sites and using fresh 29- or 31-gauge syringes minimizes local irritation.

Intravenous infusion — the 2025 pilot

Intravenous BPC 157 is not a standard protocol but has been used in clinical research settings. The 2025 pilot study discussed on the dosage page and the side effects page administered 10 mg on day one and 20 mg on day two to two adult volunteers, measuring a full panel of safety biomarkers and reporting no adverse effects. These doses are 40–80 times higher than typical subcutaneous daily doses, but IV infusion gives 100% bioavailability by definition, so direct comparison is not straightforward.

IV administration is not a recommended or practical route for most users. It requires clinical supervision, sterile equipment, and carries infection risks that subcutaneous injection does not. The 2025 pilot is interesting as tolerability data, not as a dosing recommendation.

Oral BPC 157 capsules and tablets

Oral BPC 157 capsules and tablets are the most convenient route for users who cannot or will not inject. The absorption profile is the weakest part of oral BPC 157: while the peptide is more stable in gastric acid than most peptides, systemic bioavailability is still significantly reduced compared to injection. Practical oral doses are therefore 5–10 times higher than injectable doses to achieve comparable systemic effects — typically 500 mcg to 1 mg per capsule, dosed 2–3 times daily.

This matters less for gut indications, where the peptide can act locally on gut tissue before being degraded or absorbed, and more for systemic indications like tendon repair, where the peptide needs to reach and maintain levels in distant tissue. For an injury in the shoulder, oral BPC 157 is a compromise. For ulcerative colitis, it is arguably the more direct approach.

Sublingual troches and lozenges

Sublingual BPC 157 — administered as a troche (a slowly dissolving solid dose held under the tongue or in the cheek pouch) — partially bypasses the gastric acid and first-pass liver metabolism that reduce oral capsule bioavailability. The oral mucosa is highly vascularized and allows some peptides to absorb directly into systemic circulation, though the efficiency varies with molecule size and formulation. BPC 157 troches are typically dosed at 500 mcg to 1 mg per troche, taken 2–3 times daily, held under the tongue until fully dissolved.

The bioavailability improvement from sublingual versus swallowed capsule is modest but real, and users who want oral dosing for systemic effects often prefer troches over capsules for this reason. The cost trade-off is that troches are typically more expensive to compound than capsules, and some users find the taste or texture unpleasant.

BPC 157 arginate salt — the stabilized oral form

BPC 157 arginate (often sold as "BPC 157 arginate salt" or just "stable BPC 157") is a newer oral formulation developed to address the shelf-life and gastric stability challenges of standard BPC 157 capsules. Arginate refers to the addition of arginine as a counter-ion, which stabilizes the peptide structure and improves its ability to survive the gastric environment intact. Companies marketing arginate salt formulations — including some compounding pharmacies and supplement brands — claim improved bioavailability and longer shelf stability compared to standard BPC 157 capsules.

The technical rationale is plausible: salt forms of drug molecules are a standard pharmaceutical approach to improving stability, solubility, and bioavailability. Whether the specific improvements claimed for BPC 157 arginate translate to measurable clinical differences has not been published in independent peer-reviewed research. For users committed to oral dosing and willing to pay a premium for what is claimed to be a more stable formulation, arginate salt is a reasonable choice. For users indifferent to the technicalities, standard oral capsules from a reputable source accomplish a similar purpose.

Alkaline BPC 157

"Alkaline BPC 157" is a newer formulation cluster that showed up in 2024–2025 search data with strong growth. The framing is that standard BPC 157 is acidic in solution (the isoelectric point of the peptide lands in the acidic range), and buffered "alkaline" formulations are claimed to have better tissue compatibility and absorption. Like arginate salt, this is a formulation engineering argument rather than a molecular modification — the underlying peptide is still BPC 157.

Independent pharmacological data on alkaline BPC 157 formulations is limited. Marketing claims for these products should be treated with the same skepticism applied to any novel peptide formulation: plausible mechanistic story, no controlled head-to-head data, premium pricing. If the claim is improved absorption or tissue compatibility, ask the supplier for the analytical data that supports the claim. A supplier that cannot produce that data is not selling you improved science — they are selling you marketing.

Nasal spray BPC 157

Nasal spray BPC 157 exists in the marketplace but is the least-characterized route. Intranasal peptide delivery can work well for some small peptides with appropriate formulation — insulin, oxytocin, and calcitonin have all been used nasally — but BPC 157's specific intranasal pharmacokinetics have not been published. The main appeal of nasal spray BPC 157 is speculative access to brain tissue via the olfactory route, which some users pursue for neurological indications (post-concussion syndrome, cognitive complaints).

The evidence base for nasal BPC 157 is thinner than any other route. Marketing claims are largely extrapolated from the general intranasal delivery literature rather than from studies of BPC 157 specifically. Treat nasal spray BPC 157 as experimental unless supplier data suggests otherwise.

Which route for which indication

The practical decision framework for picking a BPC 157 administration route comes down to matching the route to the target tissue and the user's tolerance for injection:

• Tendon, ligament, muscle, or joint injury: Subcutaneous or intramuscular injection. Injection near the affected area is the approach cited in most rat studies.
• Gut indications (IBS, IBD, leaky gut, ulcers): Oral capsules or arginate salt formulations are a reasonable choice because local tissue delivery is a feature. See the gut health page.
• Systemic recovery or general wellness use: Subcutaneous injection for best bioavailability; sublingual troches if injection is not acceptable.
• Neurological indications: Data is thinnest here. Nasal spray is speculatively rationalized but poorly characterized.
• Combination protocols (BPC 157 + TB-500): Both peptides are injected together in the same syringe, typically subcutaneously. See the BPC 157 and TB-500 page.

Frequently asked questions